Results 161 to 170 of about 19,473,068 (392)

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

open access: yesMolecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit   +19 more
wiley   +1 more source

Retracted: Organic Photoelectric Materials and Organic Photoelectric Devices Based on Smart Image Sensors

open access: yesAdvances in Materials Science and Engineering, 2023
Advances in Materials Science and Engineering
doaj   +1 more source

Composite structural materials [PDF]

open access: yes
Overall emphasis is on basic long-term research in the following categories: constituent materials, composite materials, generic structural elements, processing science technology; and maintaining long-term structural integrity.
Loewy, R., Wiberley, S. E.
core   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

open access: yesMolecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson   +11 more
wiley   +1 more source

Retracted: Application of Energy Saving and Environmental Protection Materials in Architectural Design

open access: yesAdvances in Materials Science and Engineering, 2023
Advances in Materials Science and Engineering
doaj   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu   +11 more
wiley   +1 more source

Retracted: Innovative Application of Nano-Organic Photochromic New Materials in Hakka Traditional Decorative Pattern Design

open access: yesAdvances in Materials Science and Engineering, 2023
Advances in Materials Science and Engineering
doaj   +1 more source

Home - About - Disclaimer - Privacy